Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Alebund Pharmaceuticals (Jiangsu) Limited
禮邦醫藥(江蘇)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 09637)

PROPOSED ADOPTION OF H SHARE AWARD SCHEME AND CLOSURE OF REGISTER OF MEMBERS

PROPOSED ADOPTION OF H SHARE AWARD SCHEME

The board (the "**Board**") of directors (the "**Director(s)**") of Alebund Pharmaceuticals (Jiangsu) Limited (the "**Company**") announces that on November 27, 2026, it resolved to propose the adoption of the 2026 H Share Award Scheme of the Company (the "**H Share Award Scheme**").

The H Share Award Scheme aims to attract, retain, and motivate key talent by aligning the interests of employees, management, and shareholders (the "**Shareholders**") of the Company, rewarding their contributions and driving the Company's sustained development and long-term success.

The H Share Award Scheme constitutes a scheme involving the existing shares of the Company as referenced under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and shall be subject to the applicable disclosure requirements under Rule 17.12 of the Listing Rules. The H Share Award Scheme does not, however, involve the issue of new shares, the transfer of treasury shares or the grant of options over any new securities of the Company under Chapter 17 of the Listing Rules. Therefore, its adoption does not require the approval of the Shareholders under the Listing Rules. Nevertheless, pursuant to the articles of association of the Company, the H Share Award Scheme and the related matters are subject to, among others, the approval of the Shareholders at the general meeting of the Company.

As part of the resolution to approve the adoption of the H Share Award Scheme at the extraordinary general meeting of the Company (the "**EGM**"), the Shareholders will authorize the Board and/or authorized person(s) to administer all matters relating to the H Share Award Scheme in accordance with the rules of the H Share Award Scheme. The details of such authorization will be set out in the circular to be despatched to Shareholders thereafter.

The proposed adoption of the H Share Award Scheme (including the authorization to the Board and/or authorized person(s) to handle matters relating to the H Share Award Scheme) is subject to Shareholders' approval at the EGM.

A circular containing, among others, the details and key terms of the H Share Award Scheme and the authorization details will be despatched to the Shareholders in due course.

CLOSURE OF REGISTER OF MEMBERS AND RECORD DATE

The EGM will be held at 2:00 p.m. on Friday, December 18, 2026. The record date for determining the eligibility of holders of H shares and unlisted shares of the Company to attend and vote at the EGM is Friday, December 18, 2026. The H share register of members of the Company will be closed from Tuesday, December 15, 2026 to Friday, December 18, 2026 (both days inclusive), during which period no transfers of H shares will be registered. To be eligible to attend and vote at the EGM, holders of H shares must lodge all completed transfer documents, together with the relevant share certificates, with the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, no later than 4:30 p.m. on Monday, December 14, 2026.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
Chairman of the Board, executive Director and Chief Executive Officer

Hong Kong, November 27, 2026

As of the date of this announcement, the Board comprises (i) Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; (ii) Dr. Lu An as a non-executive Director; and (iii) Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.